Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 3Phase 3 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 2mCRPC 1Prostatic Neoplasms 1Fallopian Tube Neoplasms 1Breast Neoplasms 1

Interventions

Prednisone 53Radiotherapy 52Docetaxel 51Leuprolide 48Goserelin 47bicalutamide 45enzalutamide 28acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 27Androgen Antagonists 27Flutamide 24Triptorelin Pamoate 22apalutamide 18Gonadotropin-Releasing Hormone 18Abiraterone Acetate 17Radiation 15abiraterone 14Zoledronic Acid 14Magnetic Resonance Spectroscopy 13gallium 68 PSMA-11 12Prednisolone 11luprolide acetate gel depot 10darolutamide 9Radiosurgery 9cabazitaxel 8Standard of Care 8Specimen Handling 8Radiotherapy, Intensity-Modulated 8Radiotherapy, Conformal 8Estramustine 8Dexamethasone 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Prostatic Neoplasms × talazoparib × Clear all
NCT04821622 2026-04-07

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Pfizer

Phase 3 Active not recruiting
599 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡